A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers

Remco de Brouwer; Wouter P Te Rijdt; Edgar T Hoorntje; Ahmad Amin; Folkert W Asselbergs; Moniek G P J Cox; Jeroen F van der Heijden; Hans Hillege; Jacco C Karper; Belend Mahmoud; Peter van der Meer; Anton Oomen; Anneline S J M Te Riele; Herman H W Silljé; Hanno L Tan; Jan Peter van Tintelen; Dirk J van Veldhuisen; Berend Daan Westenbrink; Ans C P Wiesfeld; Tineke P Willems; Paul A van der Zwaag; Arthur A M Wilde; Rudolf A de Boer; Maarten P van den Berg

doi:https://doi.org/10.1093/eurheartj/ehad292

A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers

Remco de Brouwer, Wouter P Te Rijdt, Edgar T Hoorntje, Ahmad Amin, Folkert W Asselbergs, Moniek G P J Cox, Jeroen F van der Heijden, Hans Hillege, Jacco C Karper, Belend Mahmoud, Peter van der Meer, Anton Oomen, Anneline S J M Te Riele, Herman H W Silljé, Hanno L Tan, Jan Peter van Tintelen, Dirk J van Veldhuisen, Berend Daan Westenbrink, Ans C P Wiesfeld, Tineke P WillemsPaul A van der Zwaag, Arthur A M Wilde, Rudolf A de Boer, Maarten P van den Berg

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	4284-4287
Number of pages	4
Journal	European Heart journal
Volume	44
Issue number	40
DOIs	https://doi.org/10.1093/eurheartj/ehad292
Publication status	Published - 21 Oct 2023

Keywords

Cardiomyopathy
Eplerenone
Fibrosis
Heart failure
Phospholamban
Randomized clinical trial

Access to Document

https://doi.org/10.1093/eurheartj/ehad292

Cite this

de Brouwer, R., Te Rijdt, W. P., Hoorntje, E. T., Amin, A., Asselbergs, F. W., Cox, M. G. P. J., van der Heijden, J. F., Hillege, H., Karper, J. C., Mahmoud, B., van der Meer, P., Oomen, A., Te Riele, A. S. J. M., Silljé, H. H. W., Tan, H. L., van Tintelen, J. P., van Veldhuisen, D. J., Westenbrink, B. D., Wiesfeld, A. C. P., ... van den Berg, M. P. (2023). A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers. European Heart journal, 44(40), 4284-4287. https://doi.org/10.1093/eurheartj/ehad292

@article{096a47d8fc5d43d38f4a76db675b5400,

title = "A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers",

keywords = "Cardiomyopathy, Eplerenone, Fibrosis, Heart failure, Phospholamban, Randomized clinical trial",

author = "{de Brouwer}, Remco and {Te Rijdt}, {Wouter P} and Hoorntje, {Edgar T} and Ahmad Amin and Asselbergs, {Folkert W} and Cox, {Moniek G P J} and {van der Heijden}, {Jeroen F} and Hans Hillege and Karper, {Jacco C} and Belend Mahmoud and {van der Meer}, Peter and Anton Oomen and {Te Riele}, {Anneline S J M} and Sillj{\'e}, {Herman H W} and Tan, {Hanno L} and {van Tintelen}, {Jan Peter} and {van Veldhuisen}, {Dirk J} and Westenbrink, {Berend Daan} and Wiesfeld, {Ans C P} and Willems, {Tineke P} and {van der Zwaag}, {Paul A} and Wilde, {Arthur A M} and {de Boer}, {Rudolf A} and {van den Berg}, {Maarten P}",

note = "Funding Information: This work was financially supported by the Netherlands Cardiovascular Research Initiative, an initiative supported by the Dutch Heart Foundation (The Hague, Netherlands): PREDICT 1 (CVON2012-10) and 2 (CVON 2018-30), DOSIS (CVON 2014-40) and eDETECT (CVON 2015-30). Furthermore, this study was supported by a grant (836011002) from ZonMW and the Leducq Foundation (CURE-PLaN). Eplerenone was provided by Pfizer. W.P.t.R. is supported by the Dutch Heart Foundation (Young Talent Program CVON PREDICT) and the Leducq Foundation (Postdoctoral Fellowship CURE-PLaN; Netherlands Heart Institute). B.D.W is supported by the Netherlands Organisation for Scientific Research (NWO VENI grant 016.176.147) and the Netherlands Heart Foundation Senior Clinical Scientist Grant (2019T064). P.vd.M. is supported by a grant from the European research Council (ERC CoG 101045236, DISSECT-HF) H.L.T. has received funding from the European Union's Horizon 2020 research and innovation programme under acronym ESCAPE-NET, registered under grant agreement No 733381. F.W.A. is supported by UCL Hospitals NIHR Biomedical Research Centre. R.A.d.B. is supported by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). Funding Information: Conflict of interest: R.A.d.B. is president-elect of the Dutch Cardiac Society (NVVC), member of the Executive Committee of the DELIVER-trial and has received grants from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche in the last 36 months. R.A.d.B. has received payment or honoraria from Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, and Roche in the last 36 months. J.P.v.T. has received consulting fees from StrideBio in the last 36 months. A.A.M.W. has received grants from the Dutch Heart Foundation and consulting fees from LQT Therapeutics and ARMGO in the last 36 months. A.A.M.W. additionally is a member of the advisory board of the Leap Trial.",

year = "2023",

month = oct,

day = "21",

doi = "https://doi.org/10.1093/eurheartj/ehad292",

language = "English",

volume = "44",

pages = "4284--4287",

journal = "European Heart journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "40",

}

de Brouwer, R, Te Rijdt, WP, Hoorntje, ET, Amin, A , Asselbergs, FW, Cox, MGPJ, van der Heijden, JF, Hillege, H, Karper, JC, Mahmoud, B, van der Meer, P, Oomen, A, Te Riele, ASJM, Silljé, HHW, Tan, HL, van Tintelen, JP, van Veldhuisen, DJ, Westenbrink, BD, Wiesfeld, ACP, Willems, TP, van der Zwaag, PA, Wilde, AAM, de Boer, RA & van den Berg, MP 2023, 'A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers', European Heart journal, vol. 44, no. 40, pp. 4284-4287. https://doi.org/10.1093/eurheartj/ehad292

TY - JOUR

T1 - A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers

AU - de Brouwer, Remco

AU - Te Rijdt, Wouter P

AU - Hoorntje, Edgar T

AU - Amin, Ahmad

AU - Asselbergs, Folkert W

AU - Cox, Moniek G P J

AU - van der Heijden, Jeroen F

AU - Hillege, Hans

AU - Karper, Jacco C

AU - Mahmoud, Belend

AU - van der Meer, Peter

AU - Oomen, Anton

AU - Te Riele, Anneline S J M

AU - Silljé, Herman H W

AU - Tan, Hanno L

AU - van Tintelen, Jan Peter

AU - van Veldhuisen, Dirk J

AU - Westenbrink, Berend Daan

AU - Wiesfeld, Ans C P

AU - Willems, Tineke P

AU - van der Zwaag, Paul A

AU - Wilde, Arthur A M

AU - de Boer, Rudolf A

AU - van den Berg, Maarten P

N1 - Funding Information: This work was financially supported by the Netherlands Cardiovascular Research Initiative, an initiative supported by the Dutch Heart Foundation (The Hague, Netherlands): PREDICT 1 (CVON2012-10) and 2 (CVON 2018-30), DOSIS (CVON 2014-40) and eDETECT (CVON 2015-30). Furthermore, this study was supported by a grant (836011002) from ZonMW and the Leducq Foundation (CURE-PLaN). Eplerenone was provided by Pfizer. W.P.t.R. is supported by the Dutch Heart Foundation (Young Talent Program CVON PREDICT) and the Leducq Foundation (Postdoctoral Fellowship CURE-PLaN; Netherlands Heart Institute). B.D.W is supported by the Netherlands Organisation for Scientific Research (NWO VENI grant 016.176.147) and the Netherlands Heart Foundation Senior Clinical Scientist Grant (2019T064). P.vd.M. is supported by a grant from the European research Council (ERC CoG 101045236, DISSECT-HF) H.L.T. has received funding from the European Union's Horizon 2020 research and innovation programme under acronym ESCAPE-NET, registered under grant agreement No 733381. F.W.A. is supported by UCL Hospitals NIHR Biomedical Research Centre. R.A.d.B. is supported by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). Funding Information: Conflict of interest: R.A.d.B. is president-elect of the Dutch Cardiac Society (NVVC), member of the Executive Committee of the DELIVER-trial and has received grants from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche in the last 36 months. R.A.d.B. has received payment or honoraria from Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, and Roche in the last 36 months. J.P.v.T. has received consulting fees from StrideBio in the last 36 months. A.A.M.W. has received grants from the Dutch Heart Foundation and consulting fees from LQT Therapeutics and ARMGO in the last 36 months. A.A.M.W. additionally is a member of the advisory board of the Leap Trial.

PY - 2023/10/21

Y1 - 2023/10/21

KW - Cardiomyopathy

KW - Eplerenone

KW - Fibrosis

KW - Heart failure

KW - Phospholamban

KW - Randomized clinical trial

UR - http://www.scopus.com/inward/record.url?scp=85166020798&partnerID=8YFLogxK

U2 - https://doi.org/10.1093/eurheartj/ehad292

DO - https://doi.org/10.1093/eurheartj/ehad292

M3 - Article

C2 - 37210081

SN - 0195-668X

VL - 44

SP - 4284

EP - 4287

JO - European Heart journal

JF - European Heart journal

IS - 40

ER -

A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers

Keywords

Access to Document

Other files and links

Cite this